Kearney, M F, Lee, K, Bagni, R K et al. · Advances in virology · 2011 · DOI
Researchers developed sensitive tests to detect a virus called XMRV in blood samples. They used their tests on blood and tissue samples from patients with prostate cancer, but did not find the virus in any of the blood samples they tested. This study shows that while their detection methods work well, XMRV was not present in the patients' blood.
XMRV was initially proposed as a potential infectious agent in both prostate cancer and ME/CFS. This rigorous methodological study is important because it provides highly sensitive assays for detecting XMRV, and its null findings in prostate cancer patients help clarify whether XMRV is truly associated with these conditions. The validated detection methods inform the ongoing scientific investigation into XMRV's role—or lack thereof—in ME/CFS and other diseases.
This study does not prove that XMRV is not associated with ME/CFS, as the study examined only prostate cancer patients and blood samples rather than ME/CFS populations. It also does not rule out XMRV presence in tissue reservoirs other than blood or prostate, or at different disease stages. The absence of evidence in blood does not establish causation or rule out the virus's involvement in disease pathogenesis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →